Ropeginterferon alfa-2b-njft (Besremi) is the first interferon for treating polycythemia vera and the first approved medication for this condition that can be taken regardless of the patient's treatment history. It is administered subcutaneously every two weeks.Like other interferon alfa products, ropeginterferon alfa-2b-njft has a boxed warning that it can cause or aggravate neuropsychiatric, autoimmune, ischemic, and infectious disorders, which can be life-threatening or fatal. Nurses should closely monitor patients for any persistently severe or worsening signs or symptoms of these adverse effects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.NAJ.0000822968.37066.5c | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera.
Ann Hematol
January 2025
Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong, Hong Kong, China.
Polycythemia vera (PV) is characterized by clonal hematopoietic stem or progenitor cells with constitutively active somatic mutation(s) in the Janus kinase 2 gene. Phlebotomy (Phl) and aspirin are often used alone for low-risk PV patients. However, data from the Low-PV study demonstrated that Phl and aspirin may not be adequate for patients.
View Article and Find Full Text PDFThe dosage of ropeginterferon in polycythaemia vera: Balancing efficacy, safety and pharmacoeconomics across risk categories.
Br J Haematol
January 2025
CRIMM, Azienda Ospedaliera Universitaria Careggi, Dipartimento di Medicina Sperimentale e Clinica, Università di Firenze, Florence, Italy.
The higher initial dose and accelerated titration regimen of ropeginterferon as a treatment option for certain patients with polycythaemia vera.
Br J Haematol
January 2025
The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, Hangzhou, China.
Hydronephrosis-Induced Polycythemia with Low Erythropoietin Level: A Case Report and Literature Review.
Children (Basel)
December 2024
Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704302, Taiwan.
Introduction: Polycythemia is a rare condition that can be either primary or secondary. We report a case of an adolescent with progressive hydronephrosis-induced polycythemia and low erythropoietin levels, along with a thorough literature review.
Report Of A Case: A 17-year-old girl with epilepsy had progressively elevated hemoglobin levels and low erythropoietin levels.
Fatal acute pulmonary embolism following endoscopic cyanoacrylate injection for gastric fundal varices.
Acta Gastroenterol Belg
January 2025
Department of gastroenterology, Ghent University Hospital, Ghent, Belgium.
Acute gastric variceal bleeding is a rare but serious complication of portal hypertension. Initial therapy for bleeding gastric varices focuses on acute hemostasis. In this regard, endoscopic cyanoacrylate injection (ECI) is the first-line approach.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!